Drug intelligence / Profile preview

bimatoprost + travoprost

Development stage
Preclinical
Lead developer
Allergan
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Bimatoprost + travoprost is a combination of two prostaglandin analogs used in ophthalmology to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Both agents act as selective agonists at the prostanoid FP receptor, increasing aqueous humor outflow primarily through the uveoscleral pathway and, to some extent, the trabecular meshwork. This results in reduced IOP and helps prevent optic nerve damage associated with glaucoma. Bimatoprost and travoprost have similar efficacy profiles and are generally well tolerated, though they may cause side effects such as conjunctival hyperemia or eyelash growth[4][6][8]. The combination is not widely marketed as a fixed-dose product but may be considered for sequential or adjunctive therapy when monotherapy is insufficient.

02

Targets

ABCC1 (MRP1)ABCC2 (ATP-binding cassette sub-family C member 2)PTGFR (Prostaglandin F2 alpha receptor)MRP5 (ATP-binding cassette sub-family C member 5)

Beyond the preview

Go deeper on bimatoprost + travoprost.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bimatoprost + travoprost.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call